CAS 1619931-27-9

(S)-N-(3-(1-((6-(3,4-Dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide

CAS: 1619931-27-9

Fórmula: C₂₇H₂₇N₅O₃

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 469.5350

Ref: IN-DA01KBIH

Seralutinib

CAS: 1619931-27-9

Seralutinib

Pureza: ≥98%

Peso molecular: 469.54g/mol

Ref: 54-BUP03537

(S)-N-(3-(1-((6-(3,4-Dimethoxyphenyl)Pyrazin-2-Yl)Amino)Ethyl)Phenyl)-5-Methylnicotinamide

CAS: 1619931-27-9

(S)-N-(3-(1-((6-(3,4-Dimethoxyphenyl)Pyrazin-2-Yl)Amino)Ethyl)Phenyl)-5-Methylnicotinamide

Pureza: 98%

Peso molecular: 469.54g/mol

Ref: 54-OR1023229

Seralutinib

CAS: 1619931-27-9

Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.

Fórmula: C₂₇H₂₇N₅O₃

Pureza: 99.09%

Cor e Forma: Solid

Peso molecular: 469.54

Ref: TM-T8900

Seralutinib

CAS: 1619931-27-9

Seralutinib is a small molecule inhibitor of the receptor tyrosine kinase (RTK) family. Seralutinib binds to RTKs and inhibits their activation by binding to the ATP-binding site. It specifically binds to the epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and c-Kit, which are RTKs that have been implicated in cancer progression.

Fórmula: C₂₇H₂₇N₅O₃

Pureza: Min. 95%

Peso molecular: 469.5 g/mol

Ref: 3D-UPC93127